The size of the Europe RNA Analysis Market is forecasted to worth USD 1.16 Billion by 2025 from USD 0.61 Billion in 2020, showcasing a CAGR of 13.8% from 2020 to 2025.
Increasing research and development activities in RNA sequencing and transcriptomics by biotechnology and pharmaceutical industries is predicted as one of the prime factors boosting the growth. Growing funds from government and private organizations and increasing significance for personalized medicines are to accelerate the market. For instance, Regeneron Pharmaceuticals Inc. and Alnylam Pharmaceuticals Inc. have made partnership in developing RNA therapies for chronic liver diseases and non-alcoholic steatohepatitis and efficiently other relevant diseases. Rising demand for these therapies for their wide range of applications for unsatisfied medical circumstances is propelling the need for the market.
The shortage of experienced professionals in the RNA sector, deficit of systematic bioinformatics, and data analysis tools to determine massive data produced from high throughput screening technologies are factors acting as a barrier in the RNA analysis market. Moreover, a high failure rate is expected to impede the market.
This research report on the Europe RNA Analysis Market has been segmented and sub-segmented into the following categories:
Europe is next to North America is dominating the RNA analysis market during the period. This region is accounted for as the second-largest market in the RNA analysis market. Significant investments in research and advancements in RNA platform technologies are adding fuel to the market growth. Increasing government support for RNA based therapies and accessibility of proper infrastructure in enhancing the RNA market is to propel the market growth in the region.
Germany is governing the market with extensive applications in the biotechnology and pharmaceutical sectors and utilized in drug discovery, clinical diagnostic applications, and life science research to accelerate the market in this region. Also, the rise in awareness for selected products and the mounting occurrence rate of chronic diseases. The above-aforementioned factors are about to drive the market of this region.
UK is just behind the UK in having the next highest share in the RNA analysis market due to massive spending on research and development and surging market growth. Growing consideration of legislative bodies in improving reimbursement policies has escalated the expansion in the region. Moreover, the particularity and choosiness of RNAi therapies, R&D activities, and robust products and widespread usage of RNA sequencing and a growing number of pharmaceutical industries are likely to accelerate the RNA analysis market in the European region.
Prominent Companies dominating the Europe RNA Analysis Market Profiled in the Report are Illumina Inc, Qiagen N.V, Affymetrix Inc, Agilent Technologies Inc, F. Hoffmann-La Roche Ltd, Sigma Aldrich, Fluidigm Corporation, Bio-Rad Laboratories Inc, GE Healthcare, and Thermofisher Scientific Inc.
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3.1 Executive Summary
3.2 Key Inferences
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1.2 Academic Research & Government Institutes
5.1.3 Pharmaceutical & Biotechnology Companies
5.1.4 Hospitals & Diagnostic Centers
5.1.5 Y-o-Y Growth Analysis, By End User
5.1.6 Market Attractiveness Analysis, By End User
5.1.7 Market Share Analysis, By End User
5.2.3 Polymerase Chain Reaction (PCR)
5.2.4 Sequencing Technologies
126.96.36.199 Sanger Sequencing
188.8.131.52 Next Generation Sequencing (NGS)
5.2.5 RNAi Gene Silencing
5.2.6 Y-o-Y Growth Analysis, By Type
5.2.7 Market Attractiveness Analysis, By Type
5.2.8 Market Share Analysis, By Type
5.3.2 Clinical Diagnosis
5.3.3 Drug Discovery
5.3.5 Y-o-Y Growth Analysis, By Application
5.3.6 Market Attractiveness Analysis, By Application
5.3.7 Market Share Analysis, By Application
6. Geographical Analysis
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
184.108.40.206 By Geographical Area
220.127.116.11 By End User
18.104.22.168 By Type
22.214.171.124 By Application
6.1.4 Market Attractiveness Analysis
126.96.36.199 By Geographical Area
188.8.131.52 By End User
184.108.40.206 By Type
220.127.116.11 By Application
6.1.5 Market Share Analysis
18.104.22.168 By Geographical Area
22.214.171.124 By End User
126.96.36.199 By Type
188.8.131.52 By Application
6.7 Rest of Europe
7. Strategic Analysis
7.1 PESTLE analysis
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Affymetrix Inc.
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Agilent Technologies, Inc.
8.3 Bio-Rad Laboratories, Inc.
8.4 GE Healthcare
8.5 Illumina, Inc.
8.6 Qiagen N.V.
8.7 F. Hoffmann-La Roche Ltd
8.8 Sigma-Aldrich Corporation
8.9 Thermo Fisher Scientific, Inc.
8.10 Fluidigm Corporation
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, Collaborations, and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
a) List of Tables
b) List of Figures